Evidence map›Paper›PMID 38418135›Full record

ArticleIn vivo (Athens, Greece)

The Clinical Benefit of the Modified Neutrophil-Platelet Score as a Surrogate Prognostic Marker in Patients With Resectable Gastric Cancer.

Kazuki Otani, Toru Aoyama, Yukio Maezawa, Itaru Hashimoto, Natsumi Kamiya, Aya Kato, Masakatsu Numata, Shinnosuke Kawahara, Ayako Tamagawa, Masato Nakazono and 7 more

Abstract read
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Kazuki Otani *Department of Surgery, Yokohama City University, Yokohama, Japan otani.kaz.tt@yokohama-cu.ac.jp.
Toru Aoyama *Department of Surgery, Yokohama City University, Yokohama, Japan aoyamat@yokohama-cu.ac.jp.
Yukio MaezawaDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Itaru HashimotoDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Natsumi KamiyaDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Aya KatoDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Masakatsu NumataDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Shinnosuke KawaharaDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Ayako TamagawaDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Masato NakazonoDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Hiroshi TamagawaDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Kenki SegamiDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Keisuke KazamaDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Sho SawazakiDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Norio YukawaDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Aya SaitoDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Yasushi RinoDepartment of Surgery, Yokohama City University, Yokohama, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimGastric cancer is a common cause of cancer death worldwide, especially in East Asia. This study evaluated the impact of preoperative modified Neutrophil-Platelet Score (mNPS) on the survival and recurrence of patients with resectable gastric cancer. PATIENTS AND

methodsThe study analyzed 168 patients who underwent curative gastrectomy and subsequently received adjuvant treatment for gastric cancer between 2015 and 2021. Univariate and multivariate analyses were performed to identify the risk factors for overall survival (OS) and recurrence-free survival (RFS).

resultsPatients were divided into two groups: 76 patients with an mNPS of 0 were classified into the low-mNPS group, whereas 92 patients with an mNPS of ≥1 were classified into the high-mNPS group. The 3- and 5-year OS rates in the low-mNPS group were 65.6% and 56.2%, respectively, and those in the high-mNPS group were 45.3% and 36.9%, respectively. The difference in OS between the two groups was statistically significant (p=0.007). The 3- and 5-year RFS rates in the low-mNPS group were 45.6% and 38.7%, respectively, whereas those in the high-mNPS group were 33.4% and 28.1%, respectively. The difference in RFS between the two groups was statistically significant (p=0.043). A multivariate analysis showed that the mNPS was a significant independent prognostic factor for OS and RFS.

conclusionmNPS is a potential prognostic marker for patients with gastric cancer who underwent curative gastrectomy. Higher mNPS values were associated with lower 3- and 5-year OS and RFS rates, indicating a potential correlation between elevated mNPS and worse outcomes.

Indexed as

NeutrophilsStomach NeoplasmsBiomarkers, TumorBlood PlateletsHumansPrognosisRetrospective StudiesBiomarkers, TumorGastric cancermodified NPSneutrophilplatelet

Identifiers

PMID38418135
PMCPMC10905457

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.